The proteasome: a suitable antineoplastic target.
Adams
Julian
J
Infinity Pharmaceuticals, Inc., 780 Memorial Drive, Cambridge, Massachusetts 02139, USA. Julian.Adams@ipi.com
D000970:Antineoplastic Agents / Q000494:pharmacology; D001897:Boronic Acids / Q000494:pharmacology; D000069286:Bortezomib; D018797:Cell Cycle Proteins / Q000502:physiology*; D002471:Cell Transformation, Neoplastic / Q000187:drug effects; D003546:Cysteine Endopeptidases / Q000502:physiology*; D010450:Endopeptidases / Q000502:physiology; D006801:Humans; D009097:Multienzyme Complexes / Q000037:antagonists & inhibitors* / Q000502:physiology*; D009687:Nuclear Proteins / Q000502:physiology; D046988:Proteasome Endopeptidase Complex; D011719:Pyrazines / Q000494:pharmacology; D015398:Signal Transduction / Q000502:physiology*
D000970:Antineoplastic Agents; D001897:Boronic Acids; D018797:Cell Cycle Proteins; D009097:Multienzyme Complexes; D009687:Nuclear Proteins; D011719:Pyrazines; D000069286:Bortezomib; D010450:Endopeptidases; D003546:Cysteine Endopeptidases; D046988:Proteasome Endopeptidase Complex